Adenovirus infections in solid organ transplant recipients

Current Opinion in Organ Transplantation

Volumn 14, Issue 6, 2009, Pages 625-633

  Hoffman, Jill A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Adenovirus; Cidofovir; Cytotoxic T lymphocytes; PCR; Solid organ transplant

Indexed keywords

CATECHIN; CIDOFOVIR; GANCICLOVIR; OKT 3; PROBENECID; RIBAVIRIN; STEROID; THYMOCYTE ANTIBODY; VIDARABINE; ZALCITABINE;

ADAPTIVE IMMUNITY; ADENOVIRUS INFECTION; ADOPTIVE IMMUNOTHERAPY; ANTIVIRAL THERAPY; BONE MARROW SUPPRESSION; COLITIS; CYTOTOXIC T LYMPHOCYTE; DEATH; DIAGNOSTIC TEST; ENZYME LINKED IMMUNOSORBENT ASSAY; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEART TRANSPLANTATION; HEMORRHAGIC CYSTITIS; HEPATITIS; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; INNATE IMMUNITY; INTESTINE TRANSPLANTATION; INTRAOCULAR HYPOTENSION; KIDNEY TRANSPLANTATION; LATENT PERIOD; LIVER TRANSPLANTATION; LUNG LAVAGE; LUNG TRANSPLANTATION; NEPHRITIS; NEPHROTOXICITY; ORGAN TRANSPLANTATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PNEUMONIA; POLYMERASE CHAIN REACTION; RADIOIMMUNOASSAY; RETRANSPLANTATION; REVIEW; RISK FACTOR; SEROLOGY; VIROLOGY; VIRUS DETECTION; VIRUS ISOLATION; VIRUS LOAD;

ADENOVIRIDAE; ADENOVIRUS INFECTIONS, HUMAN; ANTIVIRAL AGENTS; CHILD, PRESCHOOL; EARLY DIAGNOSIS; GRAFT REJECTION; HUMANS; IMMUNITY, INNATE; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY, ADOPTIVE; ORGAN TRANSPLANTATION; POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; VIROLOGY; VIRUS LATENCY;

EID: 74349117009     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3283324e1b     Document Type: Review

References (141)

1. Rubin RH, Kemmerly SA, Conti D, et al. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis. Transpl Infect Dis 2000; 2:112-117.
2. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357:2601-2614.
3. Cherry JD, Chen TK. Adenoviruses. In: Feigin RD, Cherry JD, Demmler GJ, Kaplan SL, editors. Textbook of pediatric infectious diseases, 6th ed. Philadelphia, Pennsylvania: Saunders; 2009. pp. 1949-1972.
4. Wold WSM. Adenoviruses. In: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE, editors. Fields' virology, 5th ed. Philadelphia, Pennsylvania: Lippincott Williams & Wilkins; 2007. pp. 2396-2436.
5. Berk AJ, Adenoviridae TE. The viruses and their replication. In: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE, editors. Fields' virology, 5th ed. Philadelphia, Pennsylvania: Lippincott Williams & Wilkins; 2007. pp. 2356-2394.
6. Jones MS II, Harrach B, Ganac RD, et al. New adenovirus species found in a patient presenting with gastroenteritis. J Virol 2007; 81:5978-5984.
7. Zheng X, Lu X, Erdman DD, et al. Identification of adenoviruses in specimens from high-risk pediatric stem cell transplant recipients and controls. J Clin Microbiol 2008; 46:317-320.
8. Ison MG. Adenovirus infections in transplant recipients. Clin Infect Dis 2006; 43:331-339.
9. Kroes ACM, de Klerk EPA, Lankester AC, et al. Sequential emergence of multiple adenovirus serotypes after pediatric stem cell transplantation. J Clin Virol 2007; 38:341-347.
10. Hoffman JA. Adenoviral disease in pediatric solid organ transplant recipients. Pediatr Transplant 2006; 10:17-25.
11. Humar A, Kumar D, Mazzulli T, et al. A surveillance study of adenovirus infection in adult solid organ transplant recipients. Am J Transpl 2005; 5:2555-2559.
12. MichaelsMG, Green M, Wald ER, Starzl TE. Adenovirus infection in pediatric liver transplant recipients. J Infect Dis 1992; 165:170-174.
13. Cames B, Rahier J, Burtomboy G, et al. Acute adenovirus hepatitis in liver transplant recipients. J Pediatr 1992; 120:33-37.
14. McGrath D, Falagas ME, Freeman R, et al. Adenovirus infection in adult orthotopic liver transplant recipients: incidence and clinical significance. J Infect Dis 1998; 177:459-462.
15. Koneru B, Atchison R, Jaffe R, et al. Serological studies of adenoviral hepatitis following pediatric liver transplantation. Transplant Proc 1990; 22:1547-1548.
16. Englemann G, Heim A, Schmitt CP, et al. Adenovirus infection and treatment with cidofovir in children after liver transplantation. Pediatr Transpl 2009; 13:421-428.
17. McLaughlin GE, Delis S, Kashimawo L, et al. Adenovirus infection in pediatric liver and intestinal transplant recipients: utility of DNA detection by PCR. Am J Transplant 2003; 3:224-228.
18. Pinchoff RJ, Kaufmann SS, Magid MS, et al. Adenovirus infection in pediatric small bowel transplantation recipients. Transplantation 2003; 76:183-189.
19. Berho M, Torroella M, Viciana A, et al. Adenovirus enterocolitis in human small bowel transplants. Pediatr Transplant 1998; 2:277-282.
20. Parizhskaya M, Walpusk J, Mazariegos G, Jaffe R. Enteric adenovirus infection in pediatric small bowl transplant recipients. Pediatr Dev Pathol 2001; 4:122-128.
21. Ziring D, Tran R, Edelstein S, et al. Infectious enteritis after intestinal transplantation: incidence, timing, and outcome. Transplantation 2005; 79:702-709.
22. Humar A, Doucette K, Kumar D, et al. Assessment of adenovirus infection in adult lung transplant recipients using molecular surveillance. J Heart Lung Transpl 2006; 25:1441-1446.
23. Ohori NP, Michaels MG, Jaffee R, et al. Adenovirus pneumonia in lung transplant recipients. Hum Pathol 1995; 26:1073-1079.
24. Bridges ND, Mallory GB, Huddleston CB, et al. Lung transplantation in infancy and early childhood. J Heart Lung Transplant 1996; 15:895-902.
25. Bridges ND, Spray TL, Collins MH, et al. Adenovirus infection in the lung results in graft failure after lung transplantation. J Thorac Cardiovasc Surg 1998; 116:617-623.
26. Doan ML, Mallory GB, Kaplan SL, et al. Treatment of adenovirus pneumonia with cidofovir in pediatric lung transplant recipients. J Heart Lung Transplant 2007; 26:883-889.
27. Shirali GS, Ni J, Chinnock RE, et al. Association of viral genome with graft loss in children after cardiac transplantation. N Engl J Med 2001; 344:1498-1503.
28. Schowengerdt KO, Ni J, Denfield SW, et al. Diagnosis, surveillance, and epidemiologic evaluation or viral infections in pediatric cardiac transplant recipients with the use of the polymerase chain reaction. J Heart Lung Transplant 1996; 15:111-123.
29. Avery RK. Viral triggers of cardiac allograft dysfunction. N Engl J Med 2001; 344:1545-1547.
30. Seidemann K, Heim A, Pfister ED, et al. Monitoring of adenovirus infection in pediatric transplant recipients by quantitative PCR: report of six cases and review of the literature. Am J Transplant 2004; 4:2102-2108.
31. Green M, Ljungman P, Michaels MG. Adenovirus, parvovirus B19, papilloma virus, and polyomaviruses after hematopoietic stem cell or solid organ transplantation. 2nd ed. In: Bowden RA, Ljungman P, Paya CV, editors. Transplant infections, Philadelphia, Pennsylvania: Lippincott Williams & Wilkins; 2003. pp. 399-411.
32. Meyerowitz RL, Stalder H, Oxman MN, et al. Fatal disseminated adenovirus infection in a renal transplant recipient. Am J Med 1975; 59:591-598.
33. Koga S, Shindo K, Matsuya F, et al. Acute hemorrhagic cystitis caused by adenovirus following renal transplantation; review of the literature. J Urol 1993; 149:838-839.
34. Ardehali H, Volmar K, Roberts C, et al. Fatal disseminated adenoviral infection in a renal transplant patient. Transplantation 2001; 71:998-999.
35. Asim M, Chong-Lopez A, Nickeleit V. Adenovirus infection of a renal allograft. Am J Kidney Dis 2003; 41:696-701.
36. Hofland CA, Eron LJ, Washecka RM. Hemorrhagic adenovirus cystitis after renal transplantation. Transplant Proc 2004; 36:3025-3027.
37. Emovon OE, Chavin J, Rogers K, Self S. Adenovirus in kidney transplantation: an emerging pathogen? Transplantation 2004; 77:1474-1475.
38. Kim SS, Hicks J, Goldstein SL. Adenovirus pyelonephritis in a pediatric renal transplant patient. Pediatr Nephrol 2003; 18:457-461.
39. Flomenberg P, Babbitt J, Drobyski WR, et al. Increasing incidence of adenovirus disease in bone marrow transplant recipients. J Infect Dis 1994; 169:775-781.
40. Echavarria M. Adenoviruses in immunocompromised hosts. Clin Microbiol Rev 2008; 21:704-715.
41. Hernandez de Mezerville M, Tellier R, Richardson S, et al. Adenoviral infections in pediatric transplant recipients. Pediatr Infect Dis J 2006; 25:815-818.
42. Lenaerts L, De Clercq E, Naesens L. Clinical features and treatment of adenovirus infections. Rev Med Virol 2008; 18:357-374.
43. Rubin RH. The pathogenesis and clinical management of cytomegalovirus infection in the organ transplant recipient. Curr Op Infect Dis 2007; 20:399-407.
44. Leung AY, Chan M, Cheng VC, et al. Quantification of adenovirus in the lower respiratory tract of patients without clinical adenovirus-related respiratory disease. Clin Infect Dis 2005; 40:1541-1544.
45. Garnett CT, Erdman D, Xu W, Gooding LR. Prevalence and quantitation of species C adenovirus DNA in human mucosal lymphocytes. J Virol 2002; 76:10608-10616.
46. Nazir SH, Metcalf JP. Innate Immune responses to adenovirus. J Invest Med 2005; 53:292-304.
47. Murve DA. The innate immune response to adenovirus vectors. Hum Gene Ther 2004; 15:1157-1166.
48. Appledorn DM, Patial S, McBride A, et al. Adenovirus vector induced innate inflammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo. J Immunol 2008; 181:2134-2144.
49. Zhu J, Huang X, Yang Y. Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and independent pathways. J Virol 2007; 81:3170-3180.
50. Fender P, Kidd AH, Brebant R, et al. Antigenic sites on the receptor-binding domain on human adenovirus type 2 fiber. Virology 1995; 214:110-117.
51. Varghese R, Mikyas Y, Stewart PL, Ralston R. Postentry neutralization of adenovirus type 5 by an antihexon antibody. J Virol 2004; 78:12320-12332.
52. Hong SS, Habib NA, Franqueville L, et al. Identification of adenovirus penton base neutralizing epitopes by use of sera from patients who have received conditionally replicative Addl 1520 for treatment of liver tumors. J Virol 2003; 77:10366-10375.
53. Sumida SM, Truitt DM, Lemckert AAC, et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol 2005; 174:7179-7185.
54. Kitchen LW, Vaughn DW. Role of US military research programs in the development of US licensed vaccines for naturally occurring infectious diseases. Vaccine 2007; 25:7017-7030.
55. Chakrabarti S, Mautner V, Osman H, et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood 2002; 1: 1619-1627.
56. Heemskerk B, Lankester AAC, van Vreeswijk T, et al. Immune reconstitution and clearance of human adenovirus viremia in pediatric stem-cell recipients. J Infect Dis 2005; 191:520-530.
57. Feuchtinger T, Lucke J, Hamprecht K, et al. Detection of adenovirus-specific T cells in children with adenovirus infection after allogeneic stem cell transplantation. Br J Haematol 2005; 128:503-509.
58. Feuchtinger T, Lang P, Handgretinger R. Adenovirus infections after allogeneic stem cell transplantation. Leuk Lymphoma 2007; 48:244-255.
59. Myers GD, Bollard CM, Wu MF, et al. Reconstitution of adenovirus-specific cell-mediated immunity in pediatric patients after hematopoietic stem cell transplantation. Bone Marrow Transplant 2007; 39:677-686.
60. + adenovirus-specific T cells; implications for immunotherapy and gene therapy. J Virol 2003; 77:6562-6566.
61. + T cell clones recognizing endogenous antigen inhibit viral replication in vitro through cognate interaction. J Immunol 2006; 177:8851-8859.
62. + T cells. Blood 2004; 104:2432-2440.
63. + T cells stimulated by conserved adenovirus 5 hexon peptides recognize cells infected with different species of human adenovirus. Eur J Immunol 2006; 26:2410-2423.
64. Wold WSM, Doronin K, Toth K, et al. Immune responses to adenoviruses: viral invasion mechanisms and their implications for the clinic. Curr Opin Immunol 1999; 11:380-386.
65. Burgert HG, Ruzsics Z, Obermeier A, et al. Subversion of host defense mechanisms by adenoviruses. Curr Top Microbiol Immunol 2002; 269:273-318.
66. Leen AM, Bollard CM, Myers GD, Rooney CM. Adenoviral infections in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12:243-251.
67. Flomenberg P, Gutierrez E, Piaskowski V, Casper JT. Detection of adenovirus DNA in peripheral blood mononuclear cells by polymerase chain reaction assay. J Med Virol 1997; 51:182-188.
68. Heim A, Ebnet C, Harste G, Pring-Akerblom P. Rapid and quantitative detection of human adenovirus DNA by real-time PCR. J Med Virol 2003; 71:228-239.
69. Gu Z, Belzer SW, Gibson CS, et al. Multiplexed, real-time PCR for quantitative detection of human adenovirus. J Clin Microbiol 2003; 41:4636-4641.
70. Perlman J, Gibson C, Pounds SB, et al. Qualitative realtime PCR detection of adenovirus in clinical blood specimens: a comparison of plasma, whole blood and peripheral blood mononuclear cells. J Clin Virol 2007; 40:295-300.
71. Ebner K, Rauch M, Preuner S, Lion T. Typing of human adenoviruses in specimens from immunosuppressed patients by PCR fragment length analysis and real time quantitative PCR. J Clin Microbiol 2006; 44:2808-2815.
72. Madisch I, Wolfel R, Harste G, et al. Molecular identification of adenovirus sequences: a rapid scheme for early typing of human adenoviruses in diagnostic samples of immunocompetent and immunodeficient patients. J Med Virol 2006; 78:1210-1217.
73. Mahoney JB. Detection of respiratory viruses by molecular methods. Clin Microbiol Rev 2008; 21:716-747.
74. Echavarria M, Forman M, van Rol MJ, et al. Prediction of severe disseminated adenovirus infection by serum PCR. Lancet 2001; 358:384-385.
75. Schilham MW, Class EC, van Zaane W, et al. High levels of adenovirus DNA in serum correlate with fatal outcome of adenovirus infection in children after allogeneic stem-cell transplantation. Clin Infect Dis 2002; 35:526-532.
76. Lion T, Baumgartinger R, Watzinger F, et al. Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. Blood 2003; 102:1114-1120.
77. Walls T, Hawrami K, Shingadia D, et al. Polymerase chain reaction in the management of disseminated adenovirus infection after stem cell transplantation. Pediatr Infect Dis J 2004; 23:1167-1169.
78. Leruez-Ville M, Minard V, Lacaille F, et al. Real-time blood plasma polymerase chain reaction for management of disseminated adenovirus infection. Clin Infect Dis 2004; 38:45-52.
79. Kampmann B, Cubitt D, Walls T, et al. Improved outcome for children with disseminated adenoviral infection following allogeneic stem cell transplantation. Br J Hem 2005; 130:595-603.
80. Claas EC, Schilham MW, de Brouwer CS, et al. Internally controlled real-time PCR monitoring of adenovirus DNA load in serum or plasma of transplant recipients. J Clin Microbiol 2005; 43:1738-1744.
81. van Tol MJ, Claas EC, Heemskerk B, et al. Adenovirus infection in children after allogeneic stem cell transplantation: diagnosis, treatment and immunity. Bone Marrow Transplant 2005; 35 (Suppl 1):S73-S76.
82. Erad V, Huang ML, Ferrenberg J, et al. Quantitative real time PCR for the detection of adenovirus after T cell-replete hematopoietic cell transplantation: viral load as a marker of invasive disease. Clin Infect Dis 2007; 45:958-965.
83. Gustafson I, Lindblom A, Yun Z, et al. Quantification of adenovirus DNA in unrelated donor hematopoietic stem cell transplant recipients. J Clin Virol 2008; 43:79-85.
84. Walls T, Hawrami K, Ushiro-Lumb I, et al. Adenovirus infection after pediatric bone marrow transplantation: is treatment always necessary? Clin Infect Dis 2005; 40:1244-1249.
85. De Clercq E. In search of a selective antiviral chemotherapy. Clin Microbiol Rev 1997; 10:674-693.
86. Naesens L, Lenaerts L, Andrei G, et al. Antiadenovirus activities of several classes of nucleoside and nucleotide analogues. Antimicrob Agents Chemother 2005; 49:1010-1016.
87. Lenaerts L, Naesens L. Antiviral therapy for adenovirus infection. Antiviral Res 2006; 71:172-180.
88. Nichols WG, Campbell AJP, Boeckh M. Respiratory viruses other than influenza: impact and therapeutic advances. Clin Microbiol Rev 2008; 21:274-290.
89. Morfin F, Dupuis-Girod S, Mundweiler S, et al. In vitro susceptibility of adenovirus to antiviral drugs is species-dependent. Antivir Ther 2005; 10:225-229.
90. Stock R, Harste G, Madisch I, Heim A. A rapid PCR based assay for testing antiviral agents against human adenoviruses demonstrates type specific differences in ribavirin activity. Antivir Res 2006; 72:34-41.
91. Morfin F, Dupuis-Girod S, Frobert E, et al. Differential susceptibility of adenovirus clinical isolates to cidofovir and ribavirin is not related to species alone. Antivir Ther 2009; 14:55-61.
92. Darr S, Madisch I, Heim A. Antiviral activity of cidofovir and ribavirin against the new human adenovirus subtype 14a that is associated with severe pneumonia. Clin Infect Dis 2008; 47:731-732.
93. Shetty AK, Gans HA, So S, et al. Intravenous ribavirin therapy for adenovirus pneumonia. Pediatr Pulmonol 2000; 29:69-73.
94. Emovon OE, Lin A, Howell DN, et al. Refractory adenovirus infection after simultaneous kidney-pancreas transplantation: successful treatment with intravenous ribavirin and pooled human intravenous immunoglobulin. Nephrol Dial Transplant 2003; 18:2436-2438.
95. Gavin PJ, Katz BZ. Intravenous ribavirin treatment for severe adenovirus disease immunocompromised children. Pediatrics 2002; 110:e9.
96. Bordigoni P, Carret AS, Venard V, et al. Treatment of adenovirus infections in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2001; 32:1290-1297. (Pubitemid 32405900)
97. Lankester AC, Heemskerk B, Claas EC, et al. Effect of ribavirin on the plasma viral DNA load in patients with disseminating adenovirus infection. Clin Infect Dis 2004; 38:1521.
98. Legrand F, Berrebi D, Houhou N, et al. Early diagnosis of adenovirus infection and treatment with cidofovir after bone marrow transplant in children. Bone Marrow Transplant 2001; 27:621-626.
99. Hoffman JA, Shah AJ, Ross LA, Kapoor N. Adenoviral infections and a prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001; 7:388-394.
100. Ljungman P, Ribaud P, Eyrich M, et al. Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2003; 31:481-486.
101. Nagafuji K, Aoki K, Henzan H, Kato K. Cidofovir for treating adenoviral hemorrhagic cystitis in hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2004; 34:909-914.
102. Muller WJ, Levin MJ, Shin YK. Clinical and in vitro evaluation of cidofovir for treatment of adenovirus infection in pediatric hematopoietic stem cell transplant recipients. Clin Infect Dis 2005; 41:1812-1816.
103. Symeonidis N, Jakubowski A, Pierre-Louis S. Invasive adenoviral infections in T-cell-depleted allogeneic hematopoietic stem cell transplantation: high mortality in the era of cidofovir. Transpl Infect Dis 2007; 9:108-113.
104. Yusuf U, Hale GA, Carr J. Cidofovir for the treatment of adenovirus infection in pediatric hematopoietic stem cell transplant patients. Transplantation 2006; 81:1398-1404.
105. Neofytos D, Ojha A, Mookerjee B, Wagner J. Treatment of adenovirus disease in stem cell transplant recipients with cidofovir. Biol Blood Marrow Transplant 2007; 13:74-81.
106. Anderson EJ, Guzman-Cottrill JA, Kletzel M, et al. High-risk adenovirusinfected pediatric allogeneic hematopoietic progenitor cell transplant recipients and preemptive cidofovir therapy. Pediatr Transplantation 2008; 12:219-277.
107. Carter BA, Karpen SJ, Quiros-Tejeira RE, et al. Intravenous cidofovir therapy for disseminated adenovirus in a pediatric liver transplant recipient. Transplantation 2002; 74:1050-1052.
108. Wallot MA, Dohna-Schwake C, Auth M, Nadalin S. Disseminated adenovirus infection with respiratory failure in pediatric liver transplant recipients: impact of intravenous cidofovir and inhaled nitric oxide. Pediatr Transplantation 2006; 10:121-127.
109. Polis MA, Spooner KM, Baird BF, et al. Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria. Antimicrob Agents Chemother 1995; 39:882-886.
110. Lalezari JP. Cidofovir: a new therapy for cytomegalovirus retinitis. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14 (Suppl 1):S22-S26.
111. Hedderwick SA, Greenson JK, McGaughy VR, Clark NM. Adenovirus cholecystitis in a patient with AIDS. Clin Infect Dis 1998; 26:997-999.
112. Bhadri VA, Lee-Horn L, Shaw PJ. Safety and tolerability of cidofovir in highrisk pediatric patients. Transpl Infect Dis 2009; 11: 1398-2273.
113. DeClercq E, Holy A. Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat Rev Drug Discov 2005; 4:928-940.
114. Weber JM, Ruzindana-Umunyana A, Imbeault L, Sircar S. Inhibition of adenovirus infection and adenain by green tea catechins. Antiviral Res 2003; 58:167-173.
115. Chakrabarti S, Milligan DW, Moss PAH, Mautner V. Adenovirus infections in stem cell transplant recipients: recent developments in understanding of pathogenesis, diagnosis, and management. Leuk Lymphoma 2004; 45:873-885.
116. Feuchtinger T, Mathes-Martin S, Richard Cet al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Hematol 2006; 134:64-76.
117. Myers GD, Bollard CM, Wu M-F. Reconstitution of adenovirus-specific cellmediated immunity in pediatric patients after hematopoietic stem cell transplantation. Bone Marrow Transplant 2007; 39:677-686.
118. Chakrabarti S, Collingham KE, Fegan CD, et al. Adenovirus infections following hematopoietic cell transplantation: is there a role for adoptive immunotherapy? Bone Marrow Transplant 2000; 26:305-307.
119. von Tol MJD, Kroes ACM, Schinkel J, et al. Adenovirus infection in pediatric stem cell transplant recipients: increased risk in young children with a delayed immune recovery. Bone Marrow Transplant 2005; 36:39-50.
120. Hromas R, Cornetta K, Srour E, et al. Donor leukocyte infusion as therapy of life-threatening adenoviral infections after T cell-depleted bone marrow transplantation. Blood 1994; 84:1689-1690.
121. + T cells: it may get by with a little help from its friends. J Clin Invest 2002; 110:1415-1417.
122. Lucas KG, Sun Q. Immunotherapy with virus-specific cytotoxic T lymphocytes after organ transplantation. Pediatr Transplantation 2006; 10:142-144.
123. Rooney CM, Smith CA, Ng CYC, Loftin S. Use of gene-modified virusspecific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995; 345:9-13.
124. Leen AM, Heslop HE. Cytotoxic T lymphocytes as immune-therapy in haematological practice. Br J Haematol 2008; 143:169-179.
125. Fujita Y, Rooney CM, Heslop HE. Adoptive cellular immunotherapy for viral diseases. Bone Marrow Transplant 2008; 41:193-198.
126. Hammer MH, Meyer S, Brestrich G. HLA type-independent generation of antigen-specific T cells for adoptive immunotherapy. Eur J Immunol 2005; 35:2250-2258.
127. Feuchtinger T, Richard C, Joachim S. Clinical grade generation of hexonspecific T Cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation. J Immunother 2008; 31:199-206.
128. Becker C, Pohla H, Frankenberger B, et al. Adoptive tumor therapy with T lymphocytes enriched through an IFN-gamma capture assay. Nat Med 2001; 7:1159-1162.
129. + T cells according to IFN gamma secretion for adjuvant immunotherapy. Exp Hematol 2004; 32:282-289.
130. Leen AM, Sili U, Savoldo B. Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications. Blood 2004; 103:1011-1019.
131. Fujita Y, Leen AM, Sun J, Nakazawa Y. Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy. J Immunother 2008; 31:665-674.
132. Leen A, Ratnayake M, Foster A. Contact-activated monocytes: efficient antigen presenting cells for the stimulation of antigen-specific T cells. J Immunother 2007; 30:96-107.
133. Gerdemann U, Christin AS, Vera JF. Nucleofection of DCs to generate multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host. Mol Ther 2009; 17:1616-1625.
134. Hanley PJ, Cruz CRY, Savoldo B, Leen AM. Functionally active virus-specific T-cells that target CMV, adenovirus and EBV can be expanded from naïve T-cell populations in cord blood and will target a range of viral epitopes. Blood 2009; 114:1958-1967.
135. Leen AM, Myers GD, Uluhan S, Huls MH. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006; 12:1160-1166.
136. Burns DM, Crawford DH. Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of posttransplant lymphoproliferative disease. Blood Rev 2004; 18:193-209.
137. Jameson SC. Maintaining the norm: T-cell homeostasis. Nature Rev/Immunology 2002; 2:547-556.
138. + T cells. Proc Natl Acad Sci U S A 2008; 105:18484-18489.
139. Brestrich G, Zwinger S, Fischer A. Adoptive T-Cell therapy of a lung transplanted patient with severe CMV disease and resistance to antiviral therapy. Am J Transplant 2009; 9:1-6.
140. Haque T, Wilkie GM, Jones MM, Higgins CD. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007; 110:1123-1131.
141. Savoldo B, Gross JA, Hammer MH, Zhang L. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood 2006; 108:2942-2949.